Company news
Zymeworks Inc. (NASDAQ:ZYME) news
Every Zymeworks Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Zymeworks : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q)
August 6, 2026
Zymeworks Provides Corporate Update and Reports Second Quarter 2026 Financial Results
August 6, 2026
Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026
July 16, 2026
Zymeworks to Acquire Theravance Biopharma, Inc.
June 29, 2026
Gandeeva and Zymeworks Use Cryo-EM to Accelerate Antibody Drug Discovery
June 18, 2026
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026
June 14, 2026
Zymeworks Announces Share Repurchase Program of up to $125 Million of its Common Stock
May 14, 2026
Zymeworks Provides Corporate Update and Reports First Quarter 2026 Financial Results
May 7, 2026
Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026
April 21, 2026
Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Pl...
April 17, 2026
Zymeworks to Report First Quarter 2026 Financial Results and Host Conference Call on May 7, 2026
April 16, 2026
Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth
April 9, 2026
Zymeworks Appoints Kristin Stafford as Chief Financial Officer
April 1, 2026
Zymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRα-Targeting Antibody-Drug Conjugate
March 30, 2026
Zymeworks Announces Presentations for Ziihera® (zanidatamab-hrii) at 2026 AACR Annual Meeting
March 18, 2026
Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting
March 17, 2026
Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing
March 2, 2026
Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing
March 2, 2026
Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
March 2, 2026
Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026
February 12, 2026
Zymeworks Announces Participation in Upcoming Investor Conferences
January 27, 2026
Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy
January 12, 2026
Zymeworks Outlines Strategic Priorities and Outlook for 2026
January 11, 2026
Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including m...
January 6, 2026
Zymeworks Announces Participation in Upcoming Conferences
December 2, 2025
Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer
November 18, 2025
Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating...
November 18, 2025
Zymeworks Announces Positive HERIZON-GEA-01 Phase 3 Results Supporting Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and N...
November 17, 2025
Zymeworks Provides Corporate Update and Reports Third Quarter 2025 Financial Results
November 6, 2025
Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-...
October 23, 2025
Zymeworks to Report Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025
October 16, 2025
Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-E...
October 13, 2025
Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer
October 9, 2025
InMed Pharmaceuticals Appoints Mr. Neil Klompas to It's Board of Directors
October 9, 2025
Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager
September 2, 2025
Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry
August 11, 2025
Zymeworks Provides Corporate Update and Reports Second Quarter 2025 Financial Results
August 7, 2025
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibito...
July 28, 2025
Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025
July 17, 2025
Life Sciences BC Announces 2025 Awards Winners, Honouring Excellence in Health Innovation
July 10, 2025
Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expres...
May 30, 2025
Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences
May 22, 2025
Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference
May 19, 2025
Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results
May 8, 2025
Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting
April 25, 2025
Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development
April 21, 2025
Zymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025
April 17, 2025
Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting
March 25, 2025
Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
March 5, 2025
Zymeworks Announces Achievement of $14 Million Milestone from GSK Collaboration
February 26, 2025